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Host genomic abnormalities may determine the natural history of cervical squamous intraepithelial lesions (SILs). We undertook
comparative genomic hybridisation analysis of epithelium carefully microdissected from 70 cervical SILs, the largest series to date. In
contrast to previous studies, we used frozen sections for optimal DNA quality and examined whether patterns of DNA copy number
imbalance (CNI) are characteristic of SIL grade, human papillomavirus (HPV) status and postoperative recurrence. We identified
more CNIs in cervical SIL than previously described, with more CNIs per case in high-grade squamous intraepithelial lesion (HG-SIL)
than in low-grade squamous intraepithelial lesion (LG-SIL) (P¼0.04). While some CNIs were seen at similar frequencies in HG-SIL
and LG-SIL, others, including gain on 1q, 3q and 16q, were found frequently in HG-SIL but not in LG-SIL. There were significantly
more CNIs per case in HG-SILs showing loss of the HPV16 E2 gene (a repressor of viral oncogene transcription) (P¼0.026) and in
HG-SILs that subsequently recurred (P¼0.04). Our data are consistent with sequential acquisition of CNIs in cervical SIL progression.
Higher frequency of CNI in association with E2 gene loss supports in vitro evidence that high-risk HPV integration is associated with
genomic instability. Further investigation of the clinical value of specific host genomic abnormalities in cervical SIL is warranted.
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Cervical squamous cell carcinoma (SCC) usually arises from a
subset of high-grade squamous intraepithelial lesions (HG-SIL),
which in turn are thought to arise from a subset of low-grade
squamous intraepithelial lesions (LG-SIL) (Holowaty et al, 1999;
Franco et al, 2001). Untreated SILs have the potential to regress,
persist or progress, and up to 8.6% of SILs recur locally following
complete excision (Mohamed-Noor et al, 1997; Hulman et al, 1998;
Nagai et al, 2000; Chao et al, 2004). However, the molecular
pathology of cervical SILs is poorly understood and it is currently
not possible to predict the natural history of an individual lesion.
Unnecessary follow-up of women with cervical SILs destined not
to progress or recur imposes large burdens on colposcopy services
worldwide and produces substantial adverse psychosocial con-
sequences for individual patients. There is therefore a very
important requirement for new rational and objective approaches
to improving diagnosis and prediction of outcome in cervical SIL.
Infection with high-risk human papillomavirus (HR-HPV) is
known to be an independent risk factor for progression of LG-SIL to
HG-SIL and for the development of SCC (Remmink et al, 1995;
Konno et al, 1998). However, HPV testing is inherently nonspecific at
identifying patients destined to develop cervical SCC (Sasieni, 2000)
or HG-SIL (Lorincz et al, 2002). Other biological factors of
importance in the progression of SIL or recurrence after treatment
include persistence of HR-HPV (Costa et al,2 0 0 3 ) ,i n t e g r a t i o no f
HR-HPV into host chromosomes and the acquisition of secondary
host genomic abnormalities (Lazo, 1999). Integration frequently
causes disruption of the HR-HPV E2 transcriptional repressor with
consequent deregulation of HR-HPV oncogenes, events that we have
recently demonstrated to be important in inducing high-level
genomic instability in cervical keratinocytes in vitro (Pett et al, 2004).
Very little information is available as to whether particular host
genomic abnormalities in cervical SIL may be characteristic of
lesion grade, HPV status or clinical outcome. Allelic imbalances
have been reported on numerous chromosome arms in cervical
carcinomas and small numbers of SILs (Steenbergen et al, 1996;
Chu et al, 1999; Lazo, 1999; Pulido et al, 2000), and there is some
evidence of progressive accumulation of allelic imbalances with
increasing grade of abnormality. (Larson et al, 1997; Chu et al,
1999; Luft et al, 1999; Chung et al, 2000; Lin et al, 2000; Chuaqui
et al, 2001).
Likewise, data from comparative genomic hybridisation (CGH)
have been reported for only relatively small numbers of cervical
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sSILs (Heselmeyer et al, 1996; Kirchhoff et al, 1999, 2001;
Umayahara et al, 2002). These studies have generally suggested
that relatively few copy number imbalances (CNIs) exist in SIL.
However, such data should be interpreted with caution, since all
studies used formalin-fixed paraffin-embedded tissue, in which
DNA degradation may cause difficulties with CGH, and cells
microdissected under histological control do not appear to have
been analysed in all studies (Kirchhoff et al, 1999, 2001). Moreover,
one study combined cases equivalent to LG-SIL with cases
equivalent to HG-SIL (Kirchhoff et al, 2001) and another examined
SIL adjacent to SCC (Umayahara et al, 2002), which may not
represent typical SIL. Most importantly, no study to date has
correlated the number and type of CNIs in cervical SIL with key
clinicopathological information such as HPV status and post-
surgical outcome.
We have therefore performed CGH using metaphase chromo-
some targets to investigate the number and frequency of CNIs in a
large series of 70 snap-frozen cervical SILs from 70 different
patients, in which the abnormal epithelium was microdissected
from serial frozen sections under histological control. None of the
SILs was accompanied by SCC. We had three objectives when
performing this work. Firstly, we aimed to characterise the number
and locations of CNIs in cervical HG-SIL and LG-SIL. We analysed
the stage of disease progression at which individual abnormalities
occurred, in order to identify possible pathways of progression.
We reasoned that any abnormalities present at similar frequencies
in LG-SIL and HG-SIL might represent early events in the
pathogenesis of SIL, while abnormalities present at a higher
frequency in HG-SIL than in LG-SIL might reflect those involved in
disease progression.
Secondly, we sought to identify any associations between CNI
and the state of the HPV16 E2 gene in HPV16-positive HG-SILs.
Initially, we performed HPV detection and typing on all cases
using nested PCR and reverse line hybridisation. In HG-SILs
containing HPV16, the HPV type most frequently associated with
cervical SCC (Bosch et al, 1995), we examined associations
between CNIs and the presence or absence of the HPV16 E2 and
E7 genes, as detected by PCR. We aimed to identify cases in which
HPV16 E2 was lost but HPV16 E7 was retained, as these cases
would be expected to show derepression of HR-HPV oncogenes.
Previous validation studies using Southern blotting had shown that
such E2-negative/E7-positive cases contained HPV16 integrants in
the absence of HPV16 episomes (Das et al, 1992). The E2/E7 PCR
technique was employed, as the microdissected samples did not
yield sufficient quantities of genomic DNA (gDNA) and RNA to
enable us to use optimal techniques for assessment of HR-HPV
integration, such as restriction site PCR (Thorland et al, 2000) or
amplification of papillomavirus oncogene transcripts (Wentzensen
et al, 2002). The third and final aim of our study was to assess the
clinical value of selected host and viral parameters in predicting
recurrence of HG-SIL after complete excision by large loop
excision of the transformation zone (LLETZ).
MATERIALS AND METHODS
Tissue
The experimental work was performed with the permission of the
Cambridge Local Research Ethics Committee (Ref: 03/023). The
study used gDNA extracted from SIL epithelium carefully
microdissected from frozen sections of cervical tissue. The tissue
was obtained from LLETZ samples removed by a consultant
gynaecologist from 70 different patients undergoing treatment for
cervical disease. None of the cases was associated with SCC. The
LLETZ samples were placed on ice after removal and study tissue
was removed and snap-frozen in liquid nitrogen within 30–60min.
Samples were numbered at the time of recruitment. The
histopathological diagnosis in the frozen sections for microdis-
section was agreed by two consultant histopathologists. Of the 70
cases, 51 were HG-SIL (given the prefix H; Figure 1) and 19 LG-SIL
(given the prefix L). The median patient age was 30 years (range
19–63 years). Normal cervical epithelium and stroma were
obtained from six hysterectomies performed for non-neoplastic
disease unrelated to the cervix.
Identification of disease recurrence
Cases of recurrence following complete local excision were
identified from review of patient records by appropriate medical
practitioners. The median follow-up period was 45 months (range
11–65 months), which is appropriate for assessment of local
recurrence (Mohamed-Noor et al, 1997; Hulman et al, 1998; Nagai
et al, 2000; Chao et al, 2004). Recurrence was defined as a
diagnosis of SIL of either grade by histology or of dyskaryosis of
any grade by cytology provided the original lesion was reported as
completely excised and there had been at least one negative smear
and/or biopsy between the original LLETZ and the recurrence.
‘Borderline’ cytological abnormalities were not regarded as
recurrences. All samples were anonymised and researchers were
blinded to the available clinical data until the CGH analysis was
complete.
Microdissection and DNA extraction
In all, 10 consecutive 10mm sections were cut from each frozen
tissue block. The first and last were stained with haematoxylin and
eosin (H&E) and used as guides for identifying SILs in the
intervening unstained sections. The abnormal epithelium was
microdissected and collected using sterile scalpels under stereo-
scopic visualisation in a microdissecting microscope at  15–25
magnification. Some sections were stained by H&E following
microdissection, in order to assess the accuracy of the procedure.
In all cases, at least 80% of the microdissected tissue was
composed of abnormal epithelium. The microdissected tissue
was placed in 50mlo f1 0 m M Tris/1mM EDTA (pH 8.0) buffer
containing 0.4mgml
 1 Proteinase K (Sigma, Poole UK) and
incubated at 371C overnight. Genomic DNA for HPV typing was
extracted from lysates of microdissected cells using guanidinium
isothiocyanate/silica as described (Boom et al, 1990).
HPV typing
PCR for HPV detection was performed as described previously
(Strauss et al, 1999) using the L1 consensus degenerate primers
MY09 and MY11 for the initial amplification (expected product
size 452bp) followed by a second-round nested PCR using the
GP5- and GP6-positive primers (expected product size 150bp).
HPV typing was performed by reverse line hybridisation, as
described elsewhere (Jordens et al, 2000), using probes comple-
mentary to sequences of the L1 region of HPV types 2, 6, 11, 16, 18,
31, 33, 35, 39, 41, 42, 43, 45, 50, 51, 52, 53, 54, 56, 58, 59, 61, 62, 66,
67, 70, 72, 81 and Han 831. HPV types 16, 18, 31, 33, 35, 39, 45, 51,
52, 56, 58, 59 and 66 were regarded as HR-HPV (Munoz et al,
2003), while the other types were regarded as low-risk HPV.
State of HPV16 E2 gene
Lysates of microdissected cells from HPV16-positive cases (where
available) were used to assess the presence or absence of the
HPV16 E2 gene, with reference to the HPV16 E7 gene.
A measure of 5ml of lysate was PCR amplified using the
AmpliTaq Gold kit (Applied Bioscience, Foster City, CA, USA):
25mM MgCl2,2 m M dNTPs, 5Uml
 1 AmpliTaq Gold and 20mM
primer pairs for either full-length HPV16 E2 (forward:
50-TGCGATGGATCCATGGAGACTCTTTGCCAACG-30; reverse:
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s50-TGCGATGGATTCTCATATAGACATAAATCCAG-30; expected
product size 1139bp) or full-length HPV16 E7 (forward 50-
ATGCATGGAGATACACCTAC-30; reverse 50-TGGTTTCTGAGAA
CAGATGGG-30; expected product size 294bp). HPV16 DNA in the
pSPHPV-16 plasmid (Stanley et al, 1989) was used as a positive
control.
Samples were considered positive for a particular reaction when
a band of the appropriate size was clearly identified. Cases showing
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L2 24  0 
L13 28  ILE  0 
L15 47 31,  52 0 
L19 19 1 
L17 39 No  f/u  11  2 
L1  30    11, 43, 45  2
L10  24  No f/u  11, 16 3
L18 27 16 3
L3 35    66    4
L8 33 16
L7 23 16
L16 28
L9 27  11,  16,  33,  39 
L6 20 
L11 36  R-LG
L4 63 6 
L12 27
L5 21 
4
5
6
6
8
8
9
9
10
L14 27  ILE  16 13
H28 51 16 0
H47 24 0
H32 35    53 0
H9 27  16,  35  0
H43 31  No  f/u  16  0
H39 25 16,  33 1
H46 29 16,  31  1
H18 23 3
H22 21 3
H27 24 3
H4 19    31,  16  3
H13 26    16  3
H44 32  16,  52 3
H1 54    16  4
H3  49  6, 16, 33, 39 4
H15 27 16,  33 
State of 
HPV16 E2
gene 
Present 
Present 
Absent
 Absent 
Present 
Present 4
H20 28 5
H10 29  No  f/u  31  5
H6 27    16  5
H33 31    16  Present 5
H14 42 16   Absent 5
H17 32  52,  66 6
H21 31  6
H31  32  11, 16, 33, 39  Present  6
H36 35  R-MD  16,  33  Present 6
H23 36    16  Absent 6
H35 28  R-LG  16   Absent 6
H12 40 70 7 
H49 38    31  7
H48 31    16  Present 7
H45 39  16,  31  Absent  7
H2 38  ILE  31  8
H50 22  R-LG  16,  31,  52  8
H40  30    16, 18, 58  9
H37 30    16  Absent 9
H24 38    31  11
H42 32  12
H11 27 16,  52 12
H30 27 16 12
H34 33 16 12
H41 31  R-LG  16   Absent 
 Absent 
 Absent 
12
H26 36    16  Absent 13
H16 35  R-LG  31,  33 14
H51 41  R-HG  15
H25 29 16 15
H38 31  ILE  16  Present 15
H29 43 16   Absent 15
H19  40 16, 33  Absent  16
H5 34  17
H7 20    33 18
H8 27  ILE  16   Absent  20
Figure 1 Clinicopathological data and frequency of CNIs in the 70 SILs studied. Prefix L denotes low-grade SIL and prefix H denotes high-grade SIL.
Clinical outcome is shown if noteworthy. (ILE¼inadequate local excision; No f/u¼no follow-up data available; R-LG¼recurred with a histological diagnosis
of LG-SIL; R-HG¼recurred with a histological diagnosis of HG-SIL; R-MiD¼recurred with cytological mild dyskaryosis). Also listed are patient age; HPV
types detected in the 53 cases analysed; the presence or absence of the HPV16 E2 gene in cases of HG-SIL that were HPV16 positive and tested (n¼23);
and the number of chromosome arms showing DNA CNI. Cases are sorted by a grade of SIL and then ranked by the number of arms showing CNI. For
each arm, white boxes indicate no CNI, green boxes indicate gain, red boxes indicate loss and green/red striped boxes indicate gain and loss on the same
arm. No data are shown for chromosomes 16p, 19 and 22, for which analysis by CGH is unreliable. In all 23 cases of HG-SIL tested for the state of the
HPV16 E2 gene, the HPV16 E7 gene was detectable.
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sequivocal positivity were not encountered in this study. All
amplifications were preformed in triplicate. On every occasion, the
presence or absence of a PCR product band was consistent for all
three replicates.
Comparative genomic hybridisation
A measure of 5ml of lysate of microdissected cells was used in a
primary degenerate oligonucleotide primed (DOP) PCR reaction as
described previously (Roberts et al, 1999). Test probes were made
by labelling 250ng of primary DOP products in a secondary DOP
reaction incorporating digoxigenin-11-dUTP (Boehringer Man-
nheim, Germany). Reference DNA was obtained from normal male
peripheral blood lymphocytes and subjected to two rounds of
DOP–PCR, using biotin-16-dUTP in the secondary labelling
reaction (Boehringer Mannheim, Germany). The test and reference
DNAs were sex mismatched in order to provide an internal
control.
Probes were made by ethanol coprecipitating 500ng of test and
reference products together with 5mg of Cot-1 DNA (Roche
Diagnostics, Lewes, UK). Hybridisation to normal male meta-
phase spreads (Vysis, Richmond, UK) was as described
previously (Sanoudou et al, 2000; Roberts et al, 2001). The
biotin and digoxigenin labels were detected using avidin-Cy3
(Amersham Pharmacia Biotech, Little Chalfont, UK) and
antidigoxigenin fluorescein isothiocyanate (FITC)-conjugated
Fab fragments (Roche Diagnostics, Lewes, UK), respectively
(Roberts et al, 2001).
For each case, seven to 12 metaphases were captured on an
Axioplan II epifluorescence microscope (Zeiss, Welwyn Garden
City, UK) equipped with narrow bandpass filter blocks for DAPI,
Cy3 and FITC, a Sensys charge-coupled device camera (Photo-
metrics, Tucson, AZ, USA) and SmartCapture VP imaging
software (Digital Scientific, Cambridge, UK). Images were
assessed using Quips CGH Analysis and Interpretation software
(Vysis, Richmond, UK). Nine normal–normal control hybridisa-
tions were performed using six test samples from microdissected
normal ectocervical epithelium and three test samples from
microdissected normal cervical stroma. Based on the results of
these hybridisations, the green-to-red (test-to-reference) fluores-
cence intensity ratio thresholds were set to 0.85 for loss and 1.15
for gain.
Chromosomes 16p, 19 and 22 were excluded from the CGH
analysis as they yield unreliable CGH data (Kallioniemi et al, 1994;
Zitzelsberger et al, 1997). The telomere of chromosome 1p was not
excluded, as the SIL samples showed DNA gain at this region
rather than DNA loss (which can represent a spurious finding;
Zitzelsberger et al, 1997), with no evidence of such gain in the
normal–normal hybridisations.
Statistical analysis
Differences in the number of CNIs per case between sample groups
were compared using the Mann–Whitney U-test. Differences in
the frequency of individual CNIs between sample groups were
compared using the w
2 test.
RESULTS
Clinical follow-up data
Of the 70 SILs examined by CGH, five had been inadequately
excised and follow-up data were not available for four (Figure 1).
In total, 61 cases (46 HG-SIL; 15 LG-SIL) were therefore completely
excised and accompanied by adequate follow-up data. The median
follow-up time was 45 months (range 11–65 months). Seven cases
recurred (11%), of which six were HG-SIL (H16, H35, H36, H41,
H50 and H51) and one was LG-SIL (L11). Recurrence was
diagnosed by histological examination in all of these cases, except
H36 where it was diagnosed by cytology. The median time for
recurrence of the HG-SILs was 15 months (range 11–22 months).
HPV typing
Sufficient DNA was available for HPV testing following CGH in 53
of the 70 cases. HPV DNA was detected in all of these cases. In all,
15 different HPV types were detected and multiple infections were
seen in 20 (38%) cases. HR-HPV types were detected in 39 of 42
(93%) of the testable HG-SILs and in eight of 11 (73%) of the
testable LG-SILs (Figure 1). HPV16 was detected in 39 cases (33
HG-SIL, six LG-SIL), but only one case (an HG-SIL) was HPV18
positive.
E2/E7 PCR
A total of 23 HPV16-positive HG-SILs had sufficient residual DNA
to permit PCR assessment of the presence of the HPV16 E2 and E7
genes (Figure 2). In total, 14 cases (61%) harboured HPV16 E7 but
not HPV16 E2, consistent with integrated HPV16 in the absence of
HPV16 episomes. Nine cases (39%) harboured intact HPV16 E2
and HPV16 E7 genes.
Comparative genomic hybridisation
Associations with lesion grade The summary of CGH copy
number karyograms for all 70 cases examined are shown in
Figure 3 and the number and locations of chromosome arms
involved for each case is shown in Figure 1. There were more CNI
per case in HG-SIL (median 6, range 0–20; n¼51) than in LG-SIL
(median 4, range 0–13; n¼19) (P¼0.04) (Figures 1 and 4a).
The most frequently occurring abnormalities in the LG-SILs
were gain on 1p (79%), 9q (47%), 17p (37%), 17q (32%) and 20q
(32%) and loss on 4q (47%), 5q (32%), 2q (26%), 6q (26%), 9p
(26%) and 13q (21%). The most frequently occurring abnormal-
ities in the HG-SILs were gain on 1p (80%), 17q (47%), 20q (47%),
9q (45%) and 17p (27%) and loss on 4q (53%), 6q (43%), 2q (33%),
13q (25%) and 5q (24%).
Certain consistent regions of common gain and loss were
identified, particularly gain at 1pter-1p32, 3q14–21, 6p21.3–21.2
and 9q34 and loss at 2q22–32, 4q22–28, 5q14–23, 6cen-q21, 9q21,
11q12–13, 11q14–21, 12q15–21 and 13q21–22. We also noted
rarer gains at 3p21, 14q24 and 15q22 and rarer losses at 7p21, 7q21
and 14q12–13. No regions of amplification (test-to-reference
fluorescence ratio 41.5) were seen in any case.
Figure 5 shows the frequency of gain and loss of selected
chromosome arms in all cases examined. Some CNIs occurred at
essentially similar frequencies in HG-SIL and LG-SIL, including
gains on 1p and 9q and losses on 4q, 5q, 6q and 13q. In contrast,
gains on 1q, 3q and 16q were found frequently in HG-SIL but not
E7 E2 M
pSPHP-V16 H26 H33
HPV16 E2 1139 bp
HPV16 E7  294 bp
E7 E2 E7 E2
Figure 2 E2/E7 PCR in HPV16-positive HG-SILs. PCR for HPV16 E2
and HPV16 E7 genes in representative cases of HPV16-positive
HG-SILs. M¼FX DNA ladder (HT Biotechnologies Ltd, Cambridge, UK).
The positive control pSPHPV-16 plasmid contains full-length HPV16.
Whereas case H33 contains intact E7 and E2, H26 contains intact E7 but
disrupted E2.
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sat all in LG-SIL (Po0.05 for each). Gain on 3q was seen in 10 cases
of HG-SIL (20%) and was the only abnormality in one case. Gain of
6p was also seen frequently in HG-SIL (22%) but only in a single
LG-SIL.
Associations with state of the HPV16 E2 gene in HPV16-positive
HG-SIL There were more CNIs per case in the 14 HPV16-positive
HG-SIL cases with loss of the HPV16 E2 gene and retention of the
HPV16 E7 gene (median 10.5, range 3–20), compared to the nine
HPV16-positive HG-SIL cases with intact HPV16 E2 and HPV16 E7
(median 5, range 0–15) (P¼0.026) (Figure 4b). The cases with loss
of E2 also showed more frequent gain on 3q (Po0.05). On the
other hand, we did observe high numbers of CNIs in some cases of
HG-SIL in which the E2 gene was retained (e.g. case H38, which
had 15 aberrant chromosome arms).
Associations with clinical outcome in HG-SIL Of the 46 cases of
completely excised HG-SIL with adequate follow-up data, there
were more CNIs in the six cases that were destined to recur
(median 10, range 6–15) than in the 40 that did not recur (median
5.5, range 0–18) (P¼0.04) (Figure 4c). Loss of 4q (P¼0.01) and
loss of 5q (Po0.05) were more frequent in the HG-SILs destined to
recur than in those that did not recur.
DISCUSSION
We have identified more CNIs per case than previously reported in
SIL. We observed a median of four CNIs per case in LG-SIL and six
CNIs per case in HG-SIL, compared, for example, to a mean of 1.1
CNIs per case in lesions equivalent to LG-SIL and a mean of 4.1
Figure 3 Summary copy number karyogram for 19 LG-SILs (A) and 51 HG-SILs (B). Each green bar to the right of a chromosome represents a region of
DNA gain in a single case and each red bar to the left of a chromosome represents a region of DNA loss in a single case.
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sCNIs per case in lesions equivalent to HG-SIL in a previous report
(Umayahara et al, 2002). Our study has the advantages of using
frozen sections of cervical SILs (unaccompanied by SCC) from
which the lesional epithelium was microdissected, which may
allow for greater sensitivity in detecting CNIs. On the other hand, it
should be noted that the thresholds used for determination of copy
number gain and loss have been greater in previous studies of
cervical SIL (Heselmeyer et al, 1996; Kirchhoff et al, 1999;
Umayahara et al, 2002).
Our data indicate that certain recurrent CNIs occur in both
cervical LG-SIL and HG-SIL and suggest that there may also be
sequential acquisition of imbalances during the progression from
LG-SIL to HG-SIL. While the CNIs that occur at similar frequencies
in LG-SIL and HG-SIL are consistent with early events, those that
are significantly more frequent in HG-SIL may confer a selective
advantage to LG-SIL cells and contribute to progression via clonal
selection. Alternatively, the latter CNIs may represent an
advantageous consequence of increased chromosomal instability
in HG-SIL (Pett et al, 2004) and be of greater relevance in
favouring subsequent progression to SCC.
CGH losses reported here are consistent with sites of allelic
imbalance previously reported in cervical SIL and SCC (Lazo,
1999), including 3p12–3p14.1 (Larson et al, 1997; Chu et al, 1999;
Chung et al, 2000), 4p16 (Larson et al, 1997), 4q21–q35 (Larson
et al, 1997), 6p14–22 (Chatterjee et al, 2001; Steenbergen et al,
2001), 6q22–q27 (Chuaqui et al, 2001), 9p21 (Lin et al, 2000),
11p14–15 and 11q23 (Luft et al, 1999; Pulido et al, 2000). Further
investigation of these sites of potential tumour suppressor genes is
warranted.
We observed gain of 3q in 20% of 51 HG-SIL cases. Whereas this
imbalance was initially described as defining the transition to SCC
in the cervix (Heselmeyer et al, 1996), it was subsequently reported
in eight of 37 (22%) paraffin-embedded ‘dysplastic’ lesions
equivalent to HG-SIL (Kirchhoff et al, 1999; Kirchhoff et al,
2001), an observation that is supported by our data. Interestingly,
we found that six of the 10 HG-SILs in our study that showed
gain of 3q also showed loss on 3p or 13q, also supporting the
previous suggestion of an association between these abnormalities
(Kirchhoff et al, 1999). Our findings are consistent with the earlier
identification of 3q25–q27 as the consensus region of gain.
Cases of HPV16-positive HG-SIL in which the E2 gene was
disrupted showed significantly more CNIs and significantly more
frequent gain on 3q than cases in which the E2 gene was intact.
Data from the PCR approach that we used to detect E2 and E7 have
previously been shown to correlate with the physical state of HPV
in clinical specimens, as determined by Southern blotting (Das
et al, 1992). Loss of E2 (with retention of E7) is consistent with the
presence of integrated HPV16 in the absence of HPV16 episomes.
The presence of the HPV16 E2 gene could either be due to
episomal HPV16 or to integrated HPV16 in which the gene is
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Figure 4 Number of CNIs per case according to selected clinicopatho-
logical features. Plots show the median (line), interquartile range (box) and
full range (whiskers) of numbers of chromosome arms showing CNI per
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tegrants. Our finding that the E2 gene was disrupted in 14 of 23
(61%) testable HG-SILs is consistent with previous PCR data
(Tonon et al, 2001). Greater chromosomal instability following loss
of the E2 gene is likely to be associated with derepression of the
HPV16 oncogenes E7 and E6, which can cooperate in the induction
of mitotic defects and genomic instability (Duensing et al, 2000;
Plug-DeMaggio et al, 2004).
For some cases at least, loss of HR-HPV E2 may therefore be a
significant intermediate step in cervical oncogenesis, occurring
between infection with HR-HPV and the development of
chromosomal instability. Indeed, these data support our recent
in vitro observations that integration of HPV16 in cervical
keratinocytes, with disruption of the E2 gene as is typically seen
in vivo, is closely associated with the development of high-level
genomic instability (Pett et al, 2004). On the other hand, our
identification in the present study of cases of HG-SIL that retain
the HPV16 E2 gene yet show numerous CNIs (e.g. case H38, with
15 aberrant arms) is consistent with the notion that loss of E2
function is not essential for chromosomal instability to develop in
cervical keratinocytes. It should be noted, however, that the low
cell yield provided by the microdissection approach that we chose
to adopt did not enable us to assess levels of E2 gene expression in
the samples that we examined. Moreover, because of clonal
heterogeneity within SILs, cells containing the E2 gene may have
been different to those showing numerous CNIs.
Of the 46 cases of HG-SIL in our study with histologically clear
excision margins and adequate follow-up data, six (13%) recurred.
This rate of local recurrence is broadly similar to that described by
other authors (Hulman et al, 1998; Nagai et al, 2000). HG-SILs
destined to recur showed significantly more CNIs and significantly
more frequent loss of 4q and 5q than HG-SILs that did not recur.
Our observations were made on relatively small numbers of cases,
using a whole genome approach that would not be appropriate for
routine clinical use. However, our data support the notion that
detection of one or more specific host cell abnormalities (either
alone or in combination with tests of HPV type, physical state, etc.)
may ultimately prove to be of value in risk stratification and
clinical management of cervical SILs.
It is likely that shared risk factors underlie the association that
we have observed between the number of CNIs in HG-SIL and
lesional recurrence despite complete local excision. Most impor-
tant may be viral factors, such as persistence and integration of
HR-HPV (Cuzick, 1997; Cruickshank et al, 2002). However, there
may also be a role for host genetic polymorphisms, such as those
affecting TP53 (Klug et al, 2001) or local host immunity (Cuzick
et al, 2000; Maciag et al, 2000), and/or environmental factors such
as smoking, local hormonal effects and other sexually transmitted
diseases (Kjellberg et al, 2000).
In summary, we have obtained molecular cytogenetic data that
are consistent with a model of sequential acquisition of genomic
CNIs in the development and progression of cervical SIL. We show
that a high number of CNIs, as well as particular sites of imbalance,
are associated with loss of the HPV16 E2 gene in HPV16-positive
HG-SIL and with recurrence of HG-SIL after adequate local
excision. It may ultimately be possible to improve the prediction of
postsurgical outcome in SIL by assessing specific genomic
abnormalities in the excised lesion. Our findings now require
validation in a different, larger group of cases, using higher
resolution approaches.
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